PO.TB10.16 · 肿瘤生物学

使用pH敏感荧光染料实时检测ADC内化动力学

Real-time detection of ADC internalization kinetics using a pH-sensitive fluorescent dye

编号 7467 展板 18 时间 4/22 09:00–12:00 区域 Section 29 主讲 An Ouyang, PhD
分会场 Therapeutic Modulation of the Tumor Microenvironment: New Targets and Approaches 2
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

An Ouyang1, Linlin Ma2, Di Shi2, Siwen Wang1, Tianfu Zhang2, Zhicheng Dong2, YuehChun Hsieh2

1ACROBiosystems Inc., Newark, DE,2ACROBiosystems Co., Ltd., Beijing, China

摘要 Abstract

中文摘要
背景:监测抗体-药物偶联物(ADC)内化需要高度敏感且特异的方法来区分表面结合与内化的分子。为满足这一需求,我们开发了一种基于pH敏感荧光染料的内化检测试剂,可实现活细胞中内吞事件的实时可视化。该实验可对起始速率、摄取持续时间和总内化量等动态参数进行定量监测,为理解ADC作用机制、优化给药方案和完善给药策略提供关键见解。 方法与材料:将一抗(2 μg/mL)和内化检测试剂(1 μg/mL)在细胞培养基中配制、混合,并于室温孵育10 min以形成标记复合物。对于悬浮细胞,将50 μL细胞悬液(1×10⁶细胞/mL)接种到96孔板的每个孔中,并与50 μL标记复合物混合。对于贴壁细胞,每孔铺板5,000-10,000个细胞并使其贴壁。随后将培养基替换为50 μL新鲜培养基,再加入50 μL标记复合物。将细胞与标记复合物孵育0.5-24 h,然后在指定时间点通过流式细胞术或高内涵成像进行分析。 结果:将SK-BR-3(HER2+)细胞与各种抗HER2 mAb及我们的内化检测试剂共孵育。在整个孵育期间,所有受测一抗的荧光呈时间依赖性增加,信号强度随时间逐渐上升。相比之下,在阴性对照细胞系MDA-MB-468(HER2-)中未检测到阳性信号。还将SK-BR-3(HER2+)细胞在内化检测试剂存在下与抗HER2 mAb及其相应的ADC药物共孵育。内化检测信号强度随试剂浓度增加呈剂量依赖性上升趋势。SK-BR-3细胞中抗HER2抗体的内化检测信号在最初7小时内逐渐增加,随后信号达到平台期并稳定维持长达18小时。在7小时时移除试剂和抗体混合物后,2 nM抗HER2抗体组的内化信号在随后24小时内逐渐下降。 结论:所开发的内化检测试剂能够以高灵敏度、可重复性和特异性对抗体和ADC内化动力学进行实时定量监测。该试剂在HER2和CD20等不同靶点上表现出一致的性能,为研究内吞机制、比较候选抗体以及加速ADC开发和优化提供了一个稳健且通用的平台。
查看英文原文 English abstract
BACKGROUND Monitoring antibody-drug conjugate (ADC) internalization demands highly sensitive and specific methods to differentiate surface-bound from internalized molecules. To address this need, we developed an internalization detection reagent based on pH-sensitive fluorescent dyes that enable real-time visualization of endocytosis events in live cells. This assay allows quantitative monitoring of dynamic parameters such as initiation rate, uptake duration, and total internalization, providing critical insights for understanding ADC mechanisms of action, optimizing dosing regimens, and refining administration strategies. METHOD AND MATERIALS The primary antibody (2 μg/mL) and Internalization Detection reagent (1μg/mL) were prepared in cell culture medium, mixed, and incubated at room temperature for 10 min to form the labeling complex. For suspension cells, 50 μL of cell suspension (1×10⁶ cells/mL) was seeded into each well of a 96-well plate and combined with 50 μL of the labeling complex. For adherent cells, 5,000-10,000 cells were plated per well and allow to attach. The medium was then replaced with 50 μL of fresh medium prior to the addition of 50 μL of the labeling complex. Cells were incubated with the labeling complex for 0.5-24 h, followed by analysis via flow cytometry or high-content imaging at designated time points. RESULTS SK-BR-3 (HER2+) cells were incubated with various Anti-HER2 mAbs and our internalization detection reagent. Throughout the incubation period, there was a time-dependent increase in fluorescence across all tested primary antibodies, with signal intensity gradually increasing over time. In contrast, no positive signal was detected in the negative control cell line MDA-MB-468(HER2-). SK-BR-3(HER2+) cells were also incubated with anti-HER2 mAbs and their corresponding ADC drugs in presence of the internalization detection reagent. The intensity of the internalization detection signal showed a dose-dependent upward trend with increasing reagent concentration. The internalization detection signal for anti-HER2 antibody in SK-BR-3 cells increased gradually over the initial 7 hours, then the signal reached a plateau and maintained stable for up to 18 hours. Upon removal of the reagent and antibody mixture at the 7-hour mark, the internalization signal in the 2 nM anti-HER2 antibody group showed a gradual decline over the next 24 hours. CONCLUSION The developed internalization detection reagent enables real-time, quantitative monitoring of antibody and ADC internalization kinetics with high sensitivity, reproducibility, and specificity. The reagent demonstrates consistent performance across different targets such as HER2 and CD20, offering a robust and versatile platform for studying endocytosis mechanisms, comparing candidate antibodies, and accelerating ADC development and optimization.
利益披露 Disclosure
A. Ouyang, None.. L. Ma, None.. D. Shi, None.. S. Wang, None.. T. Zhang, None.. Z. Dong, None.. Y. Hsieh, None.

← 返回 AACR 2026 检索